BR112022017560A2 - Método para tratar doença inflamatória intestinal i - Google Patents

Método para tratar doença inflamatória intestinal i

Info

Publication number
BR112022017560A2
BR112022017560A2 BR112022017560A BR112022017560A BR112022017560A2 BR 112022017560 A2 BR112022017560 A2 BR 112022017560A2 BR 112022017560 A BR112022017560 A BR 112022017560A BR 112022017560 A BR112022017560 A BR 112022017560A BR 112022017560 A2 BR112022017560 A2 BR 112022017560A2
Authority
BR
Brazil
Prior art keywords
inflammatory bowel
bowel disease
treat inflammatory
subject
treatting
Prior art date
Application number
BR112022017560A
Other languages
English (en)
Portuguese (pt)
Inventor
Itescu Silviu
Original Assignee
Mesoblast Int Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900742A external-priority patent/AU2020900742A0/en
Application filed by Mesoblast Int Sarl filed Critical Mesoblast Int Sarl
Publication of BR112022017560A2 publication Critical patent/BR112022017560A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BR112022017560A 2020-03-11 2021-03-11 Método para tratar doença inflamatória intestinal i BR112022017560A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020900742A AU2020900742A0 (en) 2020-03-11 Method for treating inflammatory bowel disease I
PCT/EP2021/056191 WO2021180850A1 (en) 2020-03-11 2021-03-11 Method for treating inflammatory bowel disease i

Publications (1)

Publication Number Publication Date
BR112022017560A2 true BR112022017560A2 (pt) 2022-12-27

Family

ID=74884937

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017560A BR112022017560A2 (pt) 2020-03-11 2021-03-11 Método para tratar doença inflamatória intestinal i

Country Status (9)

Country Link
US (1) US20230172991A1 (enExample)
EP (1) EP4117691A1 (enExample)
JP (1) JP2023517636A (enExample)
KR (1) KR20220152239A (enExample)
CN (1) CN115361957A (enExample)
AU (1) AU2021234104A1 (enExample)
BR (1) BR112022017560A2 (enExample)
CA (1) CA3170915A1 (enExample)
WO (1) WO2021180850A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
WO2021180851A1 (en) * 2020-03-11 2021-09-16 Mesoblast International Sàrl Method for treating inflammatory bowel disease ii

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
US8465733B2 (en) * 2007-11-02 2013-06-18 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition containing human mesenchymal stem cell
CN104873542A (zh) * 2015-05-21 2015-09-02 北京青藤谷禧干细胞科技研究院有限公司 一种脐带间充质干细胞注射液及其制备方法和应用
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
WO2018002930A1 (en) * 2016-06-30 2018-01-04 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
WO2018182612A1 (en) * 2017-03-30 2018-10-04 Progenity Inc. Methods and ingestible devices for the regio-specific release of stem cells at the site of gastrointestinal tract disease
WO2021180851A1 (en) * 2020-03-11 2021-09-16 Mesoblast International Sàrl Method for treating inflammatory bowel disease ii

Also Published As

Publication number Publication date
JP2023517636A (ja) 2023-04-26
CN115361957A (zh) 2022-11-18
CA3170915A1 (en) 2021-09-16
AU2021234104A1 (en) 2022-09-29
WO2021180850A1 (en) 2021-09-16
EP4117691A1 (en) 2023-01-18
KR20220152239A (ko) 2022-11-15
US20230172991A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
BR112022018022A2 (pt) Método para tratar doença inflamatória intestinal ii
BR112022017560A2 (pt) Método para tratar doença inflamatória intestinal i
BR112022020042A2 (pt) Método para tratar hiperinflamação com o uso de células-tronco ou precursoras de linhagem mesenquimal
CO6331301A2 (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa
ES2550059T3 (es) Método para usar una cepa de Bacillus subtilis para la profilaxis y el tratamiento de afecciones gastrointestinales
JOP20210140A1 (ar) معالجة متلازمة الحذف 22q11.2 بكانابيديول
BR112018068986A2 (pt) composição para reduzir a expressão de mir-3120 em uma célula ou tecido de um indivíduo, método para reduzir a expressão de mir-3120 em uma célula ou tecido de um indivíduo, e método para produzir células ips
BR112022016448A2 (pt) Método para tratamento de doença do enxerto contra hospedeiro crônica
BR112018075734A2 (pt) composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
BR112021020302A2 (pt) Composição, e método de tratamento de um sujeito com câncer
EA201490512A1 (ru) Композиции, содержащие культивируемую в анаэробных условиях микробиоту кишечника человека
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
BR112023020669A2 (pt) Terapias de combinação para o tratamento de câncer
BR112023001861A2 (pt) Composições e métodos para tratamento de doenças e distúrbios
BR112017010272A2 (pt) ?método de sacarificação e co-fermentação simultâneas, melhoradas com tensoativo, de lignocelulose?
BR112021015222A2 (pt) Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1
MX2023014719A (es) Esteroide neuroactivo para el tratamiento de la enfermedad de alzheimer.
BR112022000957A2 (pt) Uso de progestógeno para inibir tempestade de citocina e composição compreendendo progestógeno
BR112022025229A2 (pt) Terapias de anticorpos para infecção por sars-cov-2
BR112022003659A2 (pt) Composições e métodos de tratamento de doenças vasculares
CL2024001618A1 (es) Derivados del ácido 3-fenil-1-benzotiofeno-2-carboxílico útiles para tratar diabetes, enfermedades renales, nash e insuficiencia cardiaca
UY39061A (es) Inhibidores macrocíclicos de rip2-cinasa
BR112023021825A2 (pt) Método para tratar síndrome da angústia respiratória aguda (sara) em pacientes específicos utilizando precursores de linhagem mesenquimal ou células tronco
MX2021015403A (es) Terapia de combinacion que comprende un conjugado de anticuerpo-farmaco anti-cd19 y un inhibidor de pi3k o un agente secundario.